Public list: Pharma Startups (6570) Eye Health (703)
Aerpio Therapeutics is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of hypox...Show all
Company (IPO / Went public)
Phone: 513-985-1920
9987 Carver Road
Suite 420
Cincinnati, 45242
Ohio, United States
Total Funding | Date of Last Funding | |
---|---|---|
Aerpio Therapeutics | $66M | Mar 16, 2017 |
Audentes Therapeutics | $212.5M | Dec 2, 2019 |
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Company | Status | Description | Investors |
---|
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Hptp-beta inhibitors | May 07, 2018 | Dec 08, 2020 | Patent |
Methods for treating vascular leak syndrome and cancer | Oct 23, 2018 | Oct 27, 2020 | Patent |
Humanized monoclonal antibodies that target ve-ptp (hptp-beta) | Nov 05, 2018 | Mar 31, 2020 | Patent |
Humanized monoclonal antibodies that target ve-ptp (hptp-beta) | Nov 05, 2018 | Mar 24, 2020 | Patent |
Prolyl hydroxylase inhibitors | Feb 20, 2018 | Feb 18, 2020 | Patent |